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Abstract
Electrolyte disorders can alter cardiac ionic currents kinetics and depending on the changes
can promote proarrhythmic or antiarrhythmic effects. The present report reviews the mecha-
nisms, electrophysiolgical (EP), electrocardiographic (ECG), and clinical consequences of elec-
trolyte disorders. Potassium (K+) is the most abundent intracellular cation and hypokalemia
is the most commont electrolyte abnormality encountered in clinical practice. The most
signifcant ECG manifestation of hypokalemia is a prominent U wave. Several cardiac and
non cardiac drugs are known to suppress the HERG K+ channel and hence the IK, and
especially in the presence of hypokalemia, can result in prolonged action potential duration
and QT interval, QTU alternans, early afterdepolarizations, and torsade de pointes ventricu-
lar tachyarrythmia (TdP VT). Hyperkalemia affects up to 8% of hospitalized patients mainly
in the setting of compromised renal function. The ECG manifestation of hyperkalemia de-
pends on serum K+ level. At 5.5–7.0 mmol/L K+, tall peaked, narrow-based T waves are seen.
At > 10.0 mmol/L K+, sinus arrest, marked intraventricular conduction delay, ventricular
techycardia, and ventricular fibrillation can develop. Isolated abnormalities of extracellular
calcium (Ca++) produce clinically significant EP effects only when they are extreme in either
direction. Hypocalcemia, frequently seen in the setting of chronic renal insufficiency, results in
prolonged ST segment and QT interval while hypercalcemia, usually seen with hyperparathy-
roidism, results in shortening of both intervals. Although magnesium is the second most
abudent intracellular cation, the significance of magnesium disorders are controversial partly
because of the frequent association of other electrolyte abnormalities. However, IV magnesium
by blocking the L-type Ca++ current can succesfully terminate TdP VT without affecting the
prolonged QT interval. Finally, despite the frequency of sodium abnormalities, particularly
hyponatremia, its EP effects are rarely clinically significant. (Cardiol J 2011; 18, 3: 233–245)
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Introduction
Cardiac arrhythmias are an expression of the
same fundamental electrophysiological (EP) principles
that underlie the normal electrical behavior of the
heart. The electrical activity of the heart depends
on transmembrane ionic gradients and the time- and
voltage-dependent alterations of their conductance.
The resting membrane potential (Vm) is calculated
by the Goldman constant field equation [1],
which incorporates the permeability (P) and activi-
ty (a) of all ionic species that contribute to it.
Vm =
RT
zF
ln
PkaKo + PNAaNao + PCLaCli
PkaKi + PNAaNai + PCLaClo
,
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Electrolyte abnormalities may generate or fa-
cilitate clinical arrhythmias, even in the setting of
normal cardiac tissue. Furthermore, electrolyte
aberrations are more likely to interact with abnor-
mal myocardial tissue to generate their own cadre
of cardiac arrhythmias. Electrolyte disorders exert
their actions by modulating the conduction of ions
across specific cardiac membrane channels; and this
in turn can result in antiarrhthmic or proarrhyth-
mic sequelae.
Potassium
Potassium is the most abundant intracellular
cation and the most important determinant of the
resting membrane potential (RMP). The EP effects
of potassium depend not only on its extracellular
concentration, but also on the direction (hypokale-
mia vs hyperkalemia) and rate of change. Hoffman
and Suckling [2] have noted that the effect of po-
tassium on the RMP is modulated by the simul-
taneous calcium concentration. The interrelation-
ship is such that an elevated calcium level decreas-
es the depolarizing effect of an elevated potassium
level, and low calcium levels diminish the depola-
rization produced by hypokalemia. When extracel-
lular potassium levels are higher than normal, the
cell membrane behaves as a potassium electrode,
as described by the Nernst equation:
Vm = –61.5 log [K+]i/[K+]o.
At levels of less than ~3 mmol/L, the transmem-
brane potential (Vm) is less than that predicted by the
Nernst equation [3], because hypokalemia reduces
membrane permeability to potassium (Pk).
Indeed, potassium currents are modulated by
the potassium gradient itself and other electrolytes
as well (Table 1) [4]. The conductance of the inward
rectifier current (IK1) is proportional to the square
root of the extracellular K concentration [K+]o [5,
6]. The dependence of the activation of the delayed
rectifier current (IKr) on the extracellular potassium
concentration [K+]o helps explain why the action
potential duration (APD) is shorter at higher [K+]o
and longer at low [K+]o concentrations (Table 1) [7].
As important as the time factor may be on the EP
impact of different potassium levels, it is equally
important to note that rapid fluctuations in extra-
cellular potassium levels do occur, especially
through transcellular shifts (Table 2). Insulin,
b-adrenergic agonists, aldosterone, and changes in
blood pH may independently affect serum potas-
sium levels [8].
Hypokalemia
Hypokalemia is the most common electrolyte
abnormality encountered in clinical practice. Potas-
sium values of less than 3.6 mmol/L are seen in over
20% of hospitalized patients [9]. As many as 10%
to 40% of patients on thiazide diuretics [10] and al-
most 50% of patients resuscitated from out-of-hos-
pital ventricular fibrillation [11] have low potassium
levels. Hypokalemia results from decreased potas-
sium intake, transcellular shift, and, most common-
ly, increased renal or extrarenal losses (Table 3).
Electrophysiological effects of hypokalemia
Hypokalemia leads to a higher (more negative)
RMP and, at least during electrical diastole, a de-
crease in membrane excitability as a result of wid-
ening of the RMP and the threshold potential (TP)
difference. Low extracellular potassium decreases
the delayed rectifier current (IKr), resulting in an
increase in the APD and a delay in repolarization.
Table 1. Modulation of potassium currents by
electrolyte concentration.
IK1, inward rectifier Its conductance is proportional
to the square root of [K+]o
The instantaneous inward
rectification on depolarization
is due to the Mg2? block at
physiologic [Mg2?]i [4]
IKr, delayed rectifier Low [K+]o decreases the
delayed rectifier current (IKr)
Ito, transient outward One type is voltage activated
and modulated by
neurotransmitters
The other type is activated
by intracellular Ca
IK(Ca) Opens in the presence of high
levels of intracellular calcium
IK(Na) Opens in the presence of high
levels of intracellular sodium
Table 2. Factors that affect the transcellular shift
of potassium.
From inside to outside From outside to inside
Acidosis Alkalosis
a-adrenergic receptor b2-adrenergic receptor
stimulation stimulation
Digitalis Insulin
Solvent drag
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It has been suggested that extracellular K+ ions are
required to open the delayed rectifier channel [7].
Most importantly, hypokalemia alters the con-
figuration of the action potential (AP), with the du-
ration of phase 2 first increasing and subsequently
decreasing, whereas the slope of phase 3 decele-
rates. The latter effect leads to an AP with a long
“tail”, resulting in an increase in the relative refrac-
tory period (RRP) and a decrease in the difference
of the resting membrane potential from the thresh-
old potential during the terminal phase of the AP.
Thus, cardiac tissue demonstrates increased excit-
ability with associated ectopy for a considerable
portion of the AP. Conduction slows because depo-
larization begins in incompletely repolarized fibers.
Furthermore, hypokalemia prolongs the plateau in
the Purkinje fibers but shortens it in the ventricu-
lar fibers [12]. The AP tail of the conducting sys-
tem prolongs more than that of the ventricles, in-
creasing the dispersion of repolarization. Hypokale-
mia increases diastolic depolarization in Purkinje
fibers, thereby increasing automaticity.
In summary, the EP effects of hypokalemia
are: (1) a decrease in conduction velocity; (2)
shortening of the effective refractory period
(ERP); (3) prolongation of the RRP; (4) increased
automaticity; and (5) early afterdepolarizations
(EADs) (Table 4).
Electrocardiographic manifestations
of hypokalemia
The electrocardiographic manifestations of
hypokalemia [13, 14] can be conceptualized as those
due to its effects on repolarization and those ema-
nating from its effects on conduction (Table 5).
The electrocardiographic (ECG) changes result-
ing from its effects on repolarization include: de-
creased amplitude and broadening of the T waves;
prominent U waves; ST segment depression; and
T and U wave fusion, which is seen in severe hypo-
kalemia (Fig. 1). When the U wave exceeds the T wave
in amplitude, the serum potassium is < 3 mmol/L.
ECG changes due to conduction abnormalities are
seen in more advanced stages of hypokalemia and
Table 5. ECG manifestations of hypokalemia.
Repolarization changes
Decreased amplitude and broadening
of the T waves
Prominent U waves
ST segment depression
T and U waves fusion (in severe hypokalemia)
Conduction abnormalities
Increase in QRS duration
Atrioventricular block
Cardiac arrest
Increase in P wave amplitude and duration
Slight prolongation of the P-R interval
Table 4. Electrophysiological effects of hypokalemia.
Decrease in conduction velocity
Shortening of the effective refractory period
Prolongation of the relative refractory period
Increased automaticity
Early afterdepolarizations
Table 3. Causes of hypokalemia.
Decreased intake
Potassium shift into the cell (see Table 2)
Renal potassium loss
Increased mineralocorticoid effects Increased flow to distal nephron
Primary or secondary aldosteronism Diuretics
Ectopic ACTH-producing tumor or Salt-losing nephropathy
Cushing’s syndrome Hypomagnesemia
Bartter’s syndrome Nonresorbable anion
Licorice Carbenicillin, penicillin
Renovascular or malignant hypertension Renal tubular acidosis (type I or II)
Congenital abnormality of steroid metabolism Congenital defect of distal nephron
Renin-producing tumor Liddle’s syndrome
Extrarenal potassium loss
Vomiting, diarrhea, laxative abuse
Villous adenoma, Zollinger-Ellison syndrome
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include: increase in QRS duration without
a concomitant change in the QRS configuration; atrio-
ventricular block (AV); cardiac arrest; increase in
P wave amplitude and duration; and slight prolon-
gation of the P–R interval.
Arrhythmogenic potential and
clinical implications of hypokalemia
Hypokalemia-induced hyperexcitability is clini-
cally manifested by an increase in supraventricular
and ventricular ectopy. In the Framingham Off-
spring Study, potassium and magnesium levels
were inversely related to the occurrence of com-
plex or frequent ventricular premature complexes
after adjustment for covariates [15].
Hypokalemia facilitates reentry by slowing
conduction during the prolonged RRP and by caus-
ing an increase in the dispersion of refractoriness.
Its suppressant effect on the Na-K pump leads to
intracellular Ca2+ overload and this facilitates the
development of delayed afterdepolarizations via
a transient inward current (Iti). Hypokalemia enhan-
ces the propensity for ventricular fibrillation in the
normal, as well as the ischemic, canine heart [16].
An association between hypokalemia and ventricu-
lar fibrillation in patients with acute myocardial in-
farction has been well established [17–19].
Several cxardiac and non cardiac drugs are
known to suppress the HERG K+ channel and hence
the IKr, and especially in the presence of hypokale-
mia, result in prolonged action potential duration
and QT interval, EADs, and torsade de pointes ven-
tricular tachyarrythmia (Figs. 2, 3) [20].
Hyperkalemia
Although less common than hypokalemia, hy-
perkalemia may affect approximately 8% of hospi-
talized patients in the United States. Hyperkalemia
is seen mainly in the setting of compromised renal
function, particularly in association with the admini-
stration of a variety of nephrotoxic medications.
Hyperkalemia may result from either decreased
excretion or a shift of potassium from within the cell
(Table 6).
Electrophysiological effects of hyperkalemia
The disproportional effects of varying levels of
hyperkalemia on the RMP and the TP explain the
initial increase in excitability and conduction veloci-
ty followed by their decrease as the potassium le-
vel increases further (Table 7). Mild-to-moderate
levels of hyperkalemia decrease the RMP (less ne-
gative) more than the TP, thereby diminishing the
difference between the two and increasing excitabi-
lity. The decrease in the slope of the upstroke of
the AP (dV/dT), one of the major determinants of
conduction velocity, is counterbalanced by a de-
crease in the RMP to TP difference, resulting in an
ultimate increase in conduction velocity [21]. Se-
vere hyperkalemia is associated with an increase
in the difference between the RMP and the TP,
leading to a decrease in excitability. Further dec-
rement in the AP upstroke (dV/dT) overwhelms the
positive effect of the TP decrease on the conduc-
tion velocity, resulting in a definitive decrease of
the latter.
Figure 1. Diagram of the ventricular action potential superimposed on the ECG at different extracellular potassium concen-
trations (4.0, 3.0, 2.0 mEq/L). The numbers on the left designate the transmembrane potential in millivolts. From [14].
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Hyperkalemia is associated with increased
membrane permeability to potassium, a conse-
quence of an increase of the inward going rectifier
[Ik1] and the delayed rectifier current (IKr) [5–7].
This accelerates the rate of repolarization and short-
ens the AP duration. Hyperkalemia preferentially
shortens the plateau of the Purkinje fibers, there-
by decreasing the dispersion of repolarization in the
ventricle [12]. Furthermore, it slows the diastolic
depolarization of the Purkinje fibers.
The effects of hyperkalemia depend on the tis-
sue involved, with the atrial myocardium being the
most sensitive, the ventricular myocardium less
sensitive, and the specialized tissue (sinoatrial node
and His bundle) the least sensitive. In other words,
the depression of excitability and conduction in the
atrium occur at lower extracellular potassium levels
than in other types of myocardial tissue, as exem-
plified by the occasional pacemaker case of atrial
noncapture and ventricular capture [22]. The sym-
pathetic nervous system seems to contribute to the
sinus node resistance to hyperkalemia [23].
Many investigators have observed regional dif-
ferences in repolarization time in the nonischemic
A
B
C
D
Figure 2. A. Twelve-lead ECG from a patient with hypokalemia and hypomagnesemia showing marked QTU prolon-
gation and QTU alternans (marked by arrowheads); B–D. Representative rhythm strips from the same patient as in A,
showing tachycardia-dependent QTU alternans and torsades de pointes [16].
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myocardium in response to hyperkalemia. Sutton
and colleagues have recorded monophasic action
potentials from the endocardium and epicardium in
open-chest dogs during graded intravenous infusion
of potassium to a plasma level of 9 mmol/L. Their
results suggest that the regional differences in re-
polarization times are mainly a result of local chang-
es in activation times rather than a direct effect on
the APD [24].
Figure 3. A, B, and C are tracings from a 39 year-old patient with end stage renal disease on dialysis who presented
with weakness and palpitations. Chemistry showed a serum potassium level of 10 mEq/L; A. Atypical bundle branch
block; the QRS is wide and is merging with the T wave; B. Ventricular tachycardia that failed to respond to adenosine
and procainamide given by paramedics; C. Resolution of above ECG changes with dialysis and normalization of
serum potassium level.
A
B
C
Table 6. Causes of hyperkalemia.
Decreased excretion
Renal failure
Renal secretory defects
Hyporeninemic hypoaldosteronism
Heparin
Drugs (ACE inhibitors, spironolactone,
triamterene, NSAIDs, trimethoprim)
Shift of potassium from within the cell
(see Table 2)
Massive release of intracellular potassium
Hypertonicity
Insulin deficiency
Hyperkalemic periodic paralysis
I II III aVR aVL aVF
V1 V2 V3 V4 V5 V6
I II III aVR aVL aVF
V1 V2 V3 V4 V5 V6
Table 7. Effect of [K+]o on RMP, TP, and Vmax in
ventricular muscle fibers of guinea pigs. From [21].
[K+]o RMP TP RMP–TP Vmax
[mM] [mV] [mV] [mV] [V/s]
2.0 99.4 72.7 26.7 236
5.4 83.0 65.1 17.9 219
10.0 65.8 51.4 14.4 178
11.5 62.8 45.6 17.2 154
13.0 60.7 41.9 18.8 103
16.2 55.4 34.7 20.7 45
RMP — resting membrane potential; TP — threshold potential;
[K+]o — extracellular potassium concentration
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An interesting phenomenon, the Zwaardema-
ker-Libbrecht effect, is the result of a change from
a low to high extracellular potassium level and mani-
fests itself by a transient arrest of pacemaker cells,
abbreviation of APD, and hyperpolarization [25–27].
This phenomenon underscores the fact that the rate
of intravenous administration of potassium is more
important — from a proarrhythmic standpoint —
than the absolute amount of potassium administered
and the final level of extracellular potassium.
Electrocardiographic manifestations
of hyperkalemia
The ECG is not a sensitive indicator of hyper-
kalemia; 50% of patients with potassium levels
greater than 6.5 mEq/L will not manifest any ECG
changes (Table 8) [14]. The ECG changes due to
mild potassium elevations (K = 5.5–7.0 mmol/L)
include tall, peaked, narrow-based T waves and fas-
cicular blocks. Moderate hyperkalemia (K = 7.5–
–10.0 mmol/L) is associated with first-degree AV
block and diminished P wave amplitude. As the
potassium level increases further, the P wave dis-
appears, and sinus arrest, as well as ST segment
depression, may develop. Atypical bundle branch
blocks (LBBB and RBBB), intraventricular conduc-
tion delays, ventricular tachycardia (Fig. 3), ventri-
cular fibrillation, and idioventricular rhythm are
more commonly seen in cases of severe hyperkale-
mia (K+ > 10.0 mmol/L). The bundle branch blocks
associated with hyperkalemia are atypical in the
sense that they involve the initial and terminal for-
ces of the QRS complex. Shifts in the QRS axis in-
dicate disproportionate conduction delays in the left
bundle fascicles. These manifestations of intraventri-
cular conduction delay correlate with a prolonged
intracardiac H–V interval [28]. As hyperkalemia
progresses, depolarization merges with repolariza-
tion, expressed in the ECG with QT shortening and
apparent ST segment elevation simulating acute
injury. The latter disappears with hemodialysis —
dialyzable current of injury [29]. The effect of hy-
perkalemia on QRS morphology of ventricular paced
beats have also been studied [30]. Hyperkalemia is
the most common electrolyte abnormality to cause
loss of capture. In patients with pacemakers, hyper-
kalemia causes two important clinical abnormalities:
(1) widening of the paced QRS complex (and paced
P wave) on the basis of delayed myocardial conduc-
tion; when the K level exceeds 7 mEq/L, the intra-
ventricular conduction velocity is usually decreased
and the paced QRS complex widens (Fig. 4); (2) in-
creased atrial and ventricular pacing thresholds with
or without increased latency [30].
The parallel changes in the AP and ECG can
be appreciated better by reviewing Figure 5 [14].
Arrhythmogenic potential and
clinical implications of hyperkalemia
Potassium and myocardial ischemia. In the
early phases of an ischemic insult, the cardiac mem-
brane becomes increasingly permeable to potas-
sium. After coronary ligation in pigs [31, 32], the
rise in extracellular potassium concentration results
in currents of injury, refractory period shortening,
conduction slowing, and ventricular fibrillation.
During ischemia, APD shortening is more pro-
nounced and the conduction velocity is slower in
failing than in control myocardium. Extracellular
potassium [K+]o reaches higher values during acute
ischemia in failing vs normal myocardium. Increased
spatial dispersion in EP parameters and [K+]o over
the ischemic border in failing hearts may explain
the higher propensity for reentrant arrhythmias
during acute regional ischemia [33].
Potassium and calcium abnormalities. The
combination of hyperkalemia and hypocalcemia has
a cumulative effect on the atrioventricular and in-
traventricular conduction delay and facilitates the
development of ventricular fibrillation. Hypercalce-
mia, through its membrane-stabilizing effect, coun-
teracts the effects of hyperkalemia on AV and in-
traventricular conduction and averts the develop-
ment of ventricular fibrillation. This protective
effect of calcium is immediate and its intravenous
administration should be the first therapeutic mea-
sure in cases of hyperkalemia.
Table 8. ECG manifestations of hyperkalemia.
Mild hyperkalemia (K = 5.5–7.5 mEq)
Tall, peaked, narrow-based T waves
Fascicular blocks (LAFB, LPFB)
Moderate hyperkalemia (K = 7.5–10.0 mEq)
First-degree atrioventricular block
Decreased P wave amplitude followed by
disappearance of the P waves and sinus arrest
ST segment depression
Severe hyperkalemia (K > 10.0 mEq)
Atypical bundle branch block (LBBB, RBBB), IVCD
Ventricular tachycardia, ventricular fibrillation,
idioventricular rhythm
LAFB — left anterior fascicular block; LPFB — left posterior fascicular
block; LBBB — left bundle branch block; RBBB — right bundle
branch block; IVCD — intraventricular conduction delay
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Potassium and digitalis. Hyperkalemia inhi-
bits glycoside binding to (Na+, K+) ATPase, de-
creases the inotropic effect of digitalis, and sup-
presses digitalis-induced ectopic rhythms. Alterna-
tively, hypokalemia increases glycoside binding to
(Na+, K+) ATPase, decreases the rate of digoxin
elimination, and potentiates the toxic effects of digi-
talis.
Calcium. Isolated abnormalities of calcium con-
centration produce clinically significant EP effects
only when they are extreme in either direction. As
expected by reviewing the Goldman equation, extra-
cellular calcium concentrations in the physiologic
range have no appreciable effect on the resting mem-
brane potential. Hypocalcemia and hypercalcemia
have opposing effects on the APD and ERP by af-
fecting intracellular calcium concentration and mod-
ulating potassium currents [2].
Hypocalcemia
Hypocalcemia is most frequently seen in the
setting of chronic renal insufficiency and is usually
associated with other electrolyte abnormalities.
Figure 4. This 12-lead ECG is from a 74 year-old patient with a history of pacemaker implantation for sick sinus
syndrome, who presented to the Emergency Room with complaints of “weakness”. He went into asystole shortly
afterwards. His potassium serum level at the time of the cardiac arrest was 10 mEq/L.
Figure 5. Diagram of an atrial and ventricular action potential superimposed on the ECG for extracellular potassium
at 4.0, 6.0, 8.0, 10.0, and 12.0 mEq/L. The numbers on the left designate the transmembrane potential in millivolts,
and the numbers at the bottom designate extra cellular potassium concentration [mEq/L]. From [14].
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Generally, hypocalcemia may result from decreased
intake or absorption or an increase in calcium loss
(Table 9).
Electrophysiological effects of hypocalcemia
Low extracellular calcium decreases the slow
inward current and intracellular calcium concentra-
tion during the AP plateau. The latter decreases
outward current, possibly via Ik(Ca), prolonging phase 2
of the AP, the total APD, and the duration of the
ERP. As a consequence of low intracellular cal-
cium, contractility decreases. Moreover, hypocal-
cemia slightly decreases the rate of diastolic depo-
larization in the Purkinje fibers and increases
excitability through a direct interaction with the sar-
colemma.
Electrocardiographic manifestations
of hypocalcemia
The ECG changes of hypocalcemia involve
a prolongation of the ST segment and QTc interval
and T wave alterations, including upright, low, flat,
or sharply inverted T waves in leads with an up-
right QRS complex (Fig. 6).
Hypercalcemia
Hypercalcemia occurs most commonly in the
setting of hyperparathyroidism or as a consequence
of several malignancies. A plethora of other causes
account for the remaining clinically encountered
cases (Table 10).
Table 9. Causes of hypocalcemia.
Decreased intake or absorption
Malabsorption
Decreased absorptive area
(small bowel bypass, short bowel)
Vitamin D deficit (decreased absorption,
decreased 25-hydroxy-D or
1,25-dihydroxy-D production)
Increased loss
Alcoholism
Chronic renal insufficiency
Diuretic therapy (furosemide, bumetanide)
Endocrine disease
Hypoparathyroidism or
pseudohypoparathyroidism
Medullary carcinoma of the thyroid
(calcitonin secretion)
Familial hypocalcemia
Physiological causes
Associated with decreased serum albumin
(normal calcium ion concentration)
Decreased end-organ response to vitamin D
Sepsis, hyperphosphatemia, induced by
aminoglycoside antibiotics, plicamycin,
loop diuretics, foscarnet
Figure 6. This 12-lead ECG is from a 24 year-old black female patient with sickle cell disease, end stage renal disease,
and hyperparathyroidism. The patient’s serum calcium level was 7 mg/dL and the potassium level was 6.5 mEq/L.
This ECG demonstrates a prolongation of the ST segment and QTc interval (leads V5 and V6).
Electrophysiological effects and electrocar-
diographic manifestations of hypercalcemia
High extracellular calcium levels shorten the
AP plateau, the total APD, and, consequently, the
242
Cardiology Journal 2011, Vol. 18, No. 3
www.cardiologyjournal.org
duration of the ERP. A study of the effect of hyper-
calcemia on the guinea pig ventricular AP suggest-
ed that a decrease in the inward Na+/Ca++ exchange
current might be largely responsible for the short-
ening of the AP [34]. Elevated extracellular Ca2+
concentration has a stabilizing effect on the mem-
brane, increasing the extent of depolarization need-
ed to initiate an AP. In addition, hypercalcemia has
a positive inotropic effect, decreases excitability
[35], and slightly increases the rate of diastolic de-
polarization in the Purkinje fibers. The ECG chang-
es as a result of hypercalcemia are limited to short-
ening or elimination of the ST segment and de-
creased QTc interval.
Magnesium
Magnesium is the second most abundant intra-
cellular cation after potassium. The significance of
magnesium disorders has been debated because of
difficulties in accurate measurement and their fre-
quent association with other electrolyte abnorma-
lities [36, 37]. It is an important cofactor in several
enzymatic reactions contributing to normal cardiovas-
cular physiology. Magnesium deficiency is common,
but its EP sequelae have evaded even the closest
scrutiny. Magnesium therapy in pharmacologic dos-
es has been beneficial in treating torsades de pointes.
Magnesium toxicity rarely occurs except in patients
with renal dysfunction.
Electrophysiological effects and
electrocardiographic manifestations of
hypomagnesemia and hypermagnesemia
In the presence of extremely low extracellular
calcium concentrations, magnesium exerts an effect
on the current or currents that modulate the dura-
tion of the ventricular AP plateau. Hoffman and
Suckling [2] found that in the presence of normal
calcium concentrations, magnesium deficiency had
little effect on the AP of the canine papillary mus-
cle. However, when the calcium concentration was
lowered to 1/10 of normal, complete omission of
magnesium in the superfusate prolonged the AP
plateau, which was already increased in duration by
low calcium, from a normal value of 100 to 150 ms
to 1000 ms or more.
Magnesium blocks the calcium channel, shifts
the steady-state inactivation curve of the fast so-
dium channel in the hyperpolarizing direction, modi-
fies the effect of hyperkalemia, and exerts modu-
lating effects on several potassium currents. Hyper-
magnesemia depresses AV and intraventricular
conduction. DiCarlo et al. [38] observed the follow-
ing ECG effects of intravenous administration of
magnesium in patients with normal baseline serum
magnesium and other electrolyte levels: (1) prolon-
gation of sinus node recovery time (SNRT) and cor-
rected SNRT; (2) prolongation of the AV nodal func-
tional, relative, and ERP; (3) a small increase in QRS
duration during ventricular pacing at cycle lengths
of 250 and 500 ms; and (4) a significant increase in
the atrial-His interval and the atrial paced cycle
length causing AV node Wenckebach conduction.
Kulick et al. [39] in studying healthier hearts,
noted the following ECG effects of intravenous
magnesium administration: (1) significant prolon-
gation of the P-R interval from 145 to 155 ms after
magnesium infusion; (2) prolongation of the atrial-
-His interval; (3) prolongation of the sinoatrial con-
duction time; (4) prolongation of the AV nodal ERP;
and (5) no significant increase in SNRT in the atrial
paced cycle length causing AV node Wenckebach
conduction or in QRS duration. Hypermagnesemia
and hypomagnesemia do not produce specific ECG
changes.
Magnesium and torsades de pointes
The administration of intravenous magnesium
sulfate to patients with prolonged Q-T interval and
torsades de pointes, whether the initial magnesium
level is normal or low, may suppress ventricular ta-
chycardia. Takanaka et al. [40] studied the effects of
Table 10. Causes of hypercalcemia.
Increased intake or absorption
Vitamin D or vitamin A excess
Endocrine disorders
Primary hyperparathyroidism or secondary
hyperparathyroidism (renal insufficiency,
malabsorption)
Acromegaly
Adrenal insufficiency
Neoplastic diseases
Tumors producing PTH-related protein
(ovary, kidney, lung)
Multiple myeloma (osteoclast-activating factor)
Miscellaneous causes
Thiazides
Sarcoidosis
Paget’s disease of the bone
Hypophosphatasia
Familial hypocalciuric hypercalcemia
Iatrogenic
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magnesium and lidocaine on the APD and on barium-
-induced EADs in canine Purkinje fibers. Their data
suggest that hypomagnesemia may be arrhyth-
mogenic when combined with hypokalemia and
bradycardia, and magnesium administration may
suppress triggered activity, mainly by directly pre-
venting the development of triggered APs. In con-
clusion, magnesium sulfate is a very effective and
safe treatment for torsades de pointes [41].
Magnesium and heart failure
In a sample of ambulatory patients with heart
failure, magnesium depletion in serum and tissue
did not appear to occur more commonly in patients
with serious ventricular arrhythmias than in pa-
tients without serious ventricular arrhythmias [42].
In patients with moderate to severe heart failure,
serum magnesium does not appear to be an inde-
pendent risk factor for either sudden cardiac death
or all-cause mortality [43]. Hypomagnesemia was
found to be associated with an increase in frequen-
cy of ventricular couplets, but it did not lead to
a higher incidence of clinical events [43].
Magnesium and myocardial infarction
Magnesium administration has been found to
have a positive effect on the consequences of myo-
cardial infarction in experimental models. Its effect
in the clinical setting of myocardial infarction has
been controversial. In the LIMIT-2 study, magne-
sium administration was noted to have a positive
effect on mortality rate, a finding that has not been
reproduced in the ISIS-4 trial [44–49].
Relationship between potassium,
magnesium, and cardiac arrhythmias
No specific EP effects or arrhythmias have
been linked to isolated magnesium deficiency.
Nonetheless, magnesium may influence the inci-
dence of cardiac arrhythmias through a direct ef-
fect, by modulating the effects of potassium, or
through its action as a calcium channel blocker.
Magnesium deficiency is thought to interfere with
the normal functioning of membrane ATPase, and
thus the pumping of sodium out of the cell and po-
tassium into the cell. This affects the transmem-
brane equilibrium of potassium, which may result
in changes in the resting membrane potential,
changes in potassium conductance across the cell
membrane, and disturbances in the repolarization
phase [50].
Sodium
Sodium is the most abundant extracellular ca-
tion, and the sodium current determines the phase 0
and amplitude of the AP. Its conductance increases
precipitously with the initiation of the AP, allowing
its transmembrane gradient to determine the first
phase of the AP, and, consequently, its ultimate
configuration. Hence, hypernatremia increases and
hyponatremia decreases phase 0 of the AP by alter-
ing the transmembrane sodium gradient. The up-
stroke of the AP is determined by the sodium gra-
dient and the transmembrane potential. Therefore,
hypernatremia, by increasing the sodium gradient,
negates many of the effects of hyperkalemia, which
decreases the transmembrane potential. By increas-
ing the amplitude of the AP, high sodium levels pro-
long the APD. In vitro, an increased Na concentra-
tion restores the normal configuration of AP that is
altered by previous treatment with sodium channel
blockers. Despite the frequency of sodium abnorma-
lities, particularly hyponatremia, its EP effects are
rarely of clinical significance.
Lithium
Although lithium is not a naturally occurring
electrolyte, it is frequently encountered clinically
in the treatment of manic-depressive disorders and,
as such, its potential adverse effects on the sinoatri-
al node should not be overlooked. Lithium is asso-
ciated with sinoatrial node dysfunction (sinus brady-
cardia, sinoatrial arrest, or exit block, either type I
or type II) and reversible T wave changes [51–53].
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